NCT05269888View on ClinicalTrials.gov

Covid-19 Vaccine Immune Response in Multiple Sclerosis

Active, not recruitingOBSERVATIONAL
Enrollment

240

Participants

Timeline

Start Date

February 16, 2022

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions
Multiple Sclerosis
Interventions
OTHER

Blood Test 1

"Blood test 1 - At 12 months (+3months) from the date of 1st Covid-19 vaccine:~Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche, T-SPOT® COVID SARS-CoV-2, Full Blood Count, Serum Immunoglobulins, Anti-VZV titres"

OTHER

Blood Test 2

"Blood test 2 - At 18 months (+3months) from the date of 1st Covid-19 vaccine:~Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche, T-SPOT® COVID SARS-CoV-2, Full Blood Count, Serum Immunoglobulins, Anti-VZV titres"

Trial Locations (1)

St4 6QG

University Hospitals of North Midlands NHS Trust, Stoke-on-Trent

All Listed Sponsors
lead

University Hospitals of North Midlands NHS Trust

OTHER